Glucosamine Supplement Linked to Higher Mortality and Alzheimer’s Progression

A University of Florida research team analyzed anonymized electronic health records from the UF Health system, comparing 24,000 patients diagnosed with Alzheimer’s disease and 41,000 patients with mild cognitive impairment (MCI). Patients who reported regular glucosamine use showed a 25 % higher five-year mortality rate than non-users, and MCI patients taking glucosamine were 25 % more likely to progress to full Alzheimer’s. The study, published in *Nature Metabolism*, also included experiments on genetically engineered mice that develop Alzheimer-like pathology.

NewsNation

Glucosamine is an amino sugar that contributes to N-glycan chains on cell-surface proteins. In Alzheimer’s brains, excess N-glycans accumulate—a process termed hyperglycosylation—that disrupts protein folding and impairs neuronal function. In mouse models, pharmacological inhibition of the enzyme that synthesizes these sugars improved cognitive performance, whereas dietary glucosamine worsened memory loss. Healthy mice showed no change, indicating a disease-specific effect.

NewsNation

The lead researcher emphasized that glucosamine is classified by the FDA as a dietary supplement, allowing over-the-counter purchase without medical supervision. While the compound appears safe for cognitively healthy individuals, the team cautions that it may accelerate decline in brains already affected by dementia. The authors stress that observational data cannot establish causality and call for randomized clinical trials to determine risk and appropriate dosing.

NewsNation

Earlier epidemiological studies reported a modest reduction in dementia risk among cognitively intact adults who used glucosamine. The current analysis does not refute those findings but suggests a divergent effect in patients with existing memory impairment. Limitations include reliance on prescription-record data rather than controlled dosing, lack of information on supplement brand or dosage, and uncertainty about applicability to other dementia subtypes.

NewsNation

The literature now contains contradictory signals: protective associations in healthy cohorts versus harmful associations in dementia cohorts. Critical gaps remain regarding dose-response relationships, duration of use, and whether similar amino-sugar supplements share the same risk profile. No randomized trial has yet tested glucosamine’s impact on cognitive trajectories.

NewsNation

• “(The Conversation) – People with Alzheimer’s disease who took the common supplement glucosamine were 25% more likely to die within five years than those who didn’t.” — Lead researcher, University of Florida

NewsNation

• “We found that blocking the enzyme that makes sugars like glucosamine improved dementia symptoms in mice.” — Lead researcher, University of Florida

NewsNation

• “While glucosamine appears safe and potentially protective for a healthy brain, it may be harmful for a brain that is already experiencing cognitive decline.” — Lead researcher, University of Florida

NewsNation

• “Our findings do not contradict those reports but qualify them.” — Lead researcher, University of Florida

NewsNation

The team will follow the roughly 8 % of dementia patients who stopped glucosamine to see if disease progression slows. They will also test N-glycan inhibitors and examine risks of similar supplements.

NewsNation